Two months into COVID-19, and generic drug prices remain in check

CMS has released their latest round of drug pricing data – this one reflecting price changes from arguably the peak of COVID-19 hysteria and supply chain pressure. The release gives us long-anticipated insight into how the drug supply chain is operating as it is pushed up against the wall by unprecedented disruption. Surveys have shown that Americans believe that the pandemic will yield drug price increases from manufacturers, and given the growing number of shortages, who can blame them? Well, the CMS data shows that everyone may be in for a surprise: overall, generic drug prices don’t appear to be budging.

Ben LinkJune 25, 2020NADAC, Medicaid, Generic, COVID, Suboxone, Buprenorphine-Naloxone, Zytiga, Abiraterone, Tacrolimus, Prograf